Loading patent…
AssigneeMabimmune Diagnostics AG
InventorsChad BROKOPP, Jan Grimm, Benoit Combaluzier, Manuel Tobias Gersbacher
Estimating the term…
Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, and chimeric antigen receptors (CARs) directed against the human FAP antigen as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
1-15. (canceled)
A monoclonal human B cell-derived anti-Fibroblast Activation Protein (FAP) antibody, or a biotechnological or synthetic derivative thereof, wherein at least one of the complementarity determining regions (CDRs) and/or variable heavy chain and/or variable light chain of the antibody are encoded by a cDNA derived from an mRNA obtained from a human memory B cell which produced an anti-FAP antibody.
Dependencies are inferred from the claim text.